Alzheimer’s disease (AD) is a neurodegenerative disorder leading to dementia. It is characterized by a progressive cognitive deficit and formation of pathological Aβ plaques and neurofibrillary tangles. The available potential therapeutic options for AD provide symptomatic relief and struggle to slow down its progression. The available therapies are associated with limitations and demonstrate low potential for curing disease pathogenesis. Therefore, an alternative approach, such as natural products and their active compounds, are being explored as a neuroprotective agent. Curcumin alone and as a mixture of its derivatives and as hybrids with several AD drugs are being investigated as a potential agent to manage AD. Several in vivo and in vitro experiments demonstrated that the mechanism of curcumin action is mainly by inhibiting Aβ and NFTs, modulating several inflammatory pathways and microglial activity, mitochondrial dysfunction, decreasing oxidative stress and lowering acetylcholinesterase activity. Several studies depict the therapeutic potential of curcumin and its collective contribution to cognitive improvement in animal models of AD. Although curcumin possesses potential in effectively combating AD pathology, further research is required to improve its pharmacokinetic properties in pre-clinical and clinical trials. There is a need to study and overcome limitations associated with curcumin in terms of bioavailability, stability, and therapeutic efficacy for its development as a promising therapeutic agent in managing neurological and other disorders.